SGIOY News and Press, Shionogi & Co. Ltd. ADR From 08/01/22

Shionogi & Co. press release ( OTCPK:SGIOF ): Q1 GAAP EPS of ¥115.13. Revenue of ¥71.84B (+4.2% Y/Y). For further details see: Shionogi & Co. GAAP EPS of ¥115.13, revenue of ¥71.84B

A group of health experts in Japanese health ministry delayed emergency approval on Wednesday for the COVID-19 pill developed by Osaka-based drugmaker Shionogi & Co. ( OTCPK:SGIOF ) ( OTCPK:SGIOY ), citing the need to continue discussions on the drug. The delay marks the...

Announcing new Phase 2b results for the company’s experimental COVID-19 therapy, S-217622, Japanese drugmaker Shionogi & Co. (OTCPK:SGIOY) (OTCPK:SGIOF) said that the once-daily oral treatment led to a rapid clearance of the virus in a trial conducted in Asia. The Phase 2b part of ...

Paxlovid, the COVID-19 pill developed by Pfizer (NYSE:PFE), is set to generate $23.6 billion in revenue in 2022 to become one of the fastest-selling treatments of all time, London-based data analytics firm Airfinity Ltd. said Friday, according to Bloomberg. While the consensus ...

Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antiviral cellular assays, antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a comp...

ViiV Healthcare, owned by GlaxoSmithKline (NYSE:GSK) with Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY), announced on Thursday that the US Food and Drug Administration (FDA) greenlighted a label update for its HIV medication, Cabenuva. The latest update has made the oral lead-in ...

Japanese officials are weighing whether to permit Shionogi & Co Ltd (OTCPK:SGIOY) (OTCPK:SGIOF) to start selling its COVID-19 antiviral pill as early as this spring, Japanese newspaper the Mainichi daily reported Monday, according to Reuters. Last month, Shionogi (OTCPK:SGI...

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Shionogi & Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

GlaxoSmithKline (NYSE:GSK) announced that ViiV Healthcare, majority-owned by the U.K. pharma giant, entered into a settlement with Gilead Sciences (NASDAQ:GILD) to end the legal battle over dolutegravir, ViiV’s antiviral medication used with other medicines to treat HIV. With its rival...

ViiV Healthcare, majority-owned by GlaxoSmithKline (NYSE:GSK), announced that the FDA approved an every-two-month dosing regimen of the company’s HIV therapy Cabenuva, a combination of cabotegravir and rilpivirine. Cabotegravir and rilpivirine were developed by ViiV and Janssen unit of...